[1]周欢欢 陈玉凤 徐书杭 刘林 刘超 楼青青.肠促胰素类降糖药物的低血糖风险[J].国际内分泌代谢杂志,2015,(05):314-318.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.007]
 Zhou Huanhuan*,Chen Yufeng,Xu Shuhang,et al.Hypoglycemic risk of incretin mimetic[J].International Journal of Endocrinology and Metabolism,2015,(05):314-318.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.007]
点击复制

肠促胰素类降糖药物的低血糖风险()
分享到:

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
期数:
2015年05期
页码:
314-318
栏目:
胰高血糖素样肽专题
出版日期:
2015-09-20

文章信息/Info

Title:
Hypoglycemic risk of incretin mimetic
作者:
周欢欢 陈玉凤 徐书杭 刘林 刘超 楼青青
210023 南京中医药大学护理学院(周欢欢,陈玉凤); 210028 南京,江苏省中医药研究院,南京中医药大学附属中西医结合医院健康教育科(刘林,楼青青),内分泌代谢病院区(徐书杭,刘超)
Author(s):
Zhou Huanhuan* Chen Yufeng Xu Shuhang Liu Lin Liu Chao Lou Qingqing.
*The College of Nursing, Nanjing University of Chinese Medicine, Nanjing 210023, China
关键词:
2型糖尿病 肠促胰素 低血糖
Keywords:
Type 2 diabetes mellitus Incretin Hypoglycemia
DOI:
DOI:10.3760/cma.j.issn.1673-4157.2015.05.007
摘要:
胰高血糖素样肽-1(GLP-1)受体激动剂和二肽基肽酶-4(DPP-4)抑制剂是两类新型的肠促胰素类降糖药物。普遍认为,GLP-1受体激动剂和DPP-4抑制剂具有不明显增加低血糖发生风险的优点。然而,这两类药物单用仍可导致低血糖发生,与不同药物联合治疗,该风险可不同程度地增加,尤其与磺脲类药物联用时。临床医师应了解GLP-1类似物和DPP-4抑制剂的低血糖风险,为2型糖尿病患者制定更合理、安全和有效的治疗方案。
Abstract:
Incretin mimetics including glucagon-like peptide-1(GLP-1)receptor agonists and dipeptidyl peptidase -4(DPP-4)inhibitors are new types of anti-hyperglycemic drugs. GLP-1 analogues and DPP-4 inhibitors are believed to have a lower risk of hypoglycemia. However, they still cause hypoglycemia, especially when combined with sulfonylureas. Clinicians should be aware of the risk of hypoglycemia of GLP-1 analogues and DPP-4 inhibitors, which can lay the foundation for developing more rational, safe and effective treatments for patients with type 2 diabetes.

参考文献/References:

[1] Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults[J]. JAMA, 2013,310(9): 948-959. [/br][2] Amiel SA, Dixon T, Mann R, et al. Hypoglycaemia in type 2 diabetes[J]. Diabet Med, 2008, 25(3): 245-254. [/br][3] 宋滇平. 磺脲类药物的低血糖风险[J]. 药品评价, 2012, 9(4):28-32. [/br][4] 杨燕, 童南伟. 2011 年《中国成人2 型糖尿病胰岛素促泌剂应用的专家共识》解读[J]. 中国实用内科杂志, 2012, 32(3):191-193. [/br][5] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2013年版)[J].中国医学前沿杂志(电子版),2015,(3):26-89. [/br][6] Salehi M, Aulinger BA, D'Alessio DA. Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins[J]. Endocr Rev, 2008, 29(3): 367-379. [/br][7] Ahrén B, Schweizer A, Dejager S, et al. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans[J]. Diabetes Obes Metab, 2011, 13(9): 775-783. [/br][8] Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study[J]. Clin Ther, 2008, 30(8): 1448-1460. [/br][9] DeFronzo RA, Ratener RE, Han J, et al. Effects of exenatide(exendin-4)on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes[J]. Diabetes Care, 2005, 28(5): 1092-1100. [/br][10] Liutkus J,Rosas Guzman J, Norwood P, et al. A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin[J]. Diabetes Obes Metab, 2010, 12(12): 1058-1065. [/br][11] Buse JB, Henry RR, Han J, et al. Effects of exenatide(exendin-4)on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes[J]. Diabetes Care, 2004, 27(11):2628-2635. [/br][12] Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide(exendin-4)on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea[J]. Diabetes Care,2005, 28(5): 1083-1091. [/br][13] Garber A,Henry R,Ratner R,et al.Liraglutide versus glimepiride monotherapy for type 2 diabetes(LEAD- 3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial [J]. Lancet, 2009, 373(9662): 473-481. [/br][14] Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes(DURATION-6): a randomised, open-label study[J]. Lancet, 2013, 381(9861): 117-124. [/br][15] Marre M, Shaw J, Brändle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes(LEAD-1 SU)[J]. Diabet Med, 2009,26(3): 268-278. [/br][16] Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes(LEAD-4 Met+TZD)[J]. Diabetes Care, 2009, 32(7): 1224-1230. [/br][17] Nauck M, Frid A, Hermansen K, et al. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study [J]. Diabetes Obes Metab, 2013, 15(3): 204-212. [/br][18] Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes [J]. Diabetes Care, 2006, 29(12): 2632-2637. [/br][19] Bergenstal RM, Wysham C, Macconell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes(DURATION-2): a randomised trial [J]. Lancet, 2010, 376(9739): 431-439. [/br][20] Nauck MA, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial [J]. Diabetes Obes Metab, 2007, 9(2): 194-205. [/br][21] Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin [J]. Diabetes Obes Metab, 2007, 9(5): 733-745. [/br][22] Pan C, Yang W, Barona JP, et al. Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial [J]. Diabet Med, 2008, 25(4): 435-441. [/br][23] Garber AJ, Schweizer A, Baron MA,et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study[J]. Diabetes Obes Metab, 2007, 9(2): 166-174. [/br][24] Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy[J]. Diabetes Obes Metab, 2009,11(2): 157-166. [/br][25] Lukashevich V, Prato SD, Araga M, et al. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea[J]. Diabetes Obes Metab, 2014, 16(5): 403-409. [/br][26] Rosenstock J, Gross JL, Aguilar-Salinas C, et al. Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with type 2 diabetes[J]. Diabet Med, 2013, 30(12): 1472-1476. [/br][27] DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone [J]. Diabetes Care, 2009, 32(9): 1649-1655. [/br][28] Hollander PL, Li J, Frederich R, et al. Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus[J]. Diab Vasc Dis Res, 2011, 8(2): 125-135. [/br][29] Chacra AR, Tan GH, Apanovitch A, et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial[J]. Int J Clin Pract, 2009, 63(9): 1395-1406. [/br][30] Araki E, Kawamori R, Inagaki N, et al. Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes[J]. Diabetes Obes Metab, 2013, 15(4): 364-371. [/br][31] Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study[J]. Diabetes Obes Metab,2011, 13(1): 65-74. [/br][32] Gomis R, Espadero RM, Jones R, et al. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study[J]. Diabetes Obes Metab, 2011, 13(7): 653-661. [/br][33] Owens DR, Swallow R, Dugit KA, et al. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study[J]. Diabet Med, 2011, 28(11): 1352-1361. [/br][34] Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes[J]. Diabetes Care, 2003, 26(6): 1902-1912.

相似文献/References:

[1]曾静波,王姮.2型糖尿病与自身免疫反应[J].国际内分泌代谢杂志,2007,(04):259.
[2]朱素君,谢锦桃,刘军,等.二甲双胍:2型糖尿病治疗的基础药[J].国际内分泌代谢杂志,2007,(04):280.
[3]李翠柳,朱大龙.破译肠道代谢信息,驱动治疗革新[J].国际内分泌代谢杂志,2014,(06):383.[doi:10.3760/cma.j.issn.1673-4157.2014.06.006]
 Li Cuiliu*,Zhu Dalong..Deciphering metabolic messages from the gut drives therapeutic innovation[J].International Journal of Endocrinology and Metabolism,2014,(05):383.[doi:10.3760/cma.j.issn.1673-4157.2014.06.006]
[4]刘艳清 易秋艳 邵加庆.肠道菌群与肥胖和糖尿病的关系[J].国际内分泌代谢杂志,2015,(01):31.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.01.007]
 Liu Yanqing,Yi Qiuyan,Shao Jiaqing..Relationship between gut microbiota, obesity and diabetes[J].International Journal of Endocrinology and Metabolism,2015,(05):31.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.01.007]
[5]姚旻 赵爱源 张宏.肠道菌群与2型糖尿病[J].国际内分泌代谢杂志,2015,(01):35.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.01.008]
 Yao Min*,Zhao Aiyuan,Zhang Hong..Relationship between gut microbiota and type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2015,(05):35.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.01.008]
[6]赵丽娟,徐宽枫,杨涛,等.SLC30A8和PTPRD基因多态性与南京地区中老年人群2型糖尿病的相关性研究[J].国际内分泌代谢杂志,2015,(03):145.[doi:10.3760/cma.j.issn.1673-4157.2015.03.001]
 Zhao Lijuan*,Xu Kuanfeng,Yang Tao,et al.Relationship between SLC30A8 and PTPRD gene polymorphisms and type 2 diabetes in middle aged and elderly people in Nanjing area[J].International Journal of Endocrinology and Metabolism,2015,(05):145.[doi:10.3760/cma.j.issn.1673-4157.2015.03.001]
[7]王洁,何媛,于珮.糖尿病肾病的相关危险因素分析[J].国际内分泌代谢杂志,2015,(03):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
 Wang Jie*,He Yuan,Yu Pei..Risk factors of diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(05):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
[8]刘帅,张萍,方毅,等.2型糖尿病合并无症状冠状动脉钙化的相关危险因素分析[J].国际内分泌代谢杂志,2015,(03):158.[doi:10.3760/cma.j.issn.1673-4157.2015.03.004]
 Liu Shuai*,Zhang Ping,Fang Yi,et al.Analysis of the risk factors related with asymptomatic coronary calcification for type 2 diabetic patients[J].International Journal of Endocrinology and Metabolism,2015,(05):158.[doi:10.3760/cma.j.issn.1673-4157.2015.03.004]
[9]徐庆海,马颖,李铁马.2型糖尿病患者高甘油三酯血症-腰围表型与甲状腺功能异常的关系[J].国际内分泌代谢杂志,2015,(04):222.[doi:10.3760/cma.j.issn.1673-4157.2015.04.002]
 Xu Qinghai,Ma Ying,Li Tiema..Association of hypertriglyceridaemic-waist phenotype with thyroid dysfunction in patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(05):222.[doi:10.3760/cma.j.issn.1673-4157.2015.04.002]
[10]潘道延,沈洁,朱筱,等.利格列汀对2型糖尿病大鼠代谢性内毒素血症的影响[J].国际内分泌代谢杂志,2015,(04):230.[doi:10.3760/cma.j.issn.1673-4157.2015.04.004]
 Pan Daoyan,Shen Jie,Zhu Xiao,et al.Effects of linagliptin on metabolic endotoxemia in type 2 diabetic rats[J].International Journal of Endocrinology and Metabolism,2015,(05):230.[doi:10.3760/cma.j.issn.1673-4157.2015.04.004]

备注/Memo

备注/Memo:
作者单位:210023 南京中医药大学护理学院(周欢欢,陈玉凤); 210028 南京,江苏省中医药研究院,南京中医药大学附属中西医结合医院健康教育科(刘林,楼青青),内分泌代谢病院区(徐书杭,刘超) 通信作者:楼青青,Email: lqq188@yahoo.com
更新日期/Last Update: 2015-09-20